ClinicalTrials.gg
RecruitingNCT03793257Updated Sep 15, 2023

The EXCEL Registry of Patients Requiring ECMO

An observational study in Critically Ill, Acute Respiratory Failure and Acute Heart Failure, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.

Primary conditionHeart ArrestRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Heart Arrest
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Heart Arrest.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Australian and New Zealand Intensive Care Research Centre · Observational

How we know

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Heart Arrest with a site in Australia — 3 open to participants now, 5 under way, 1 of them phase 3. Heart Arrest · Australia.

Started
2019
with 1 other
Observational
5 of 14
2 open now
Registered
11th of 14
by date
Lead sponsor
3 of 14
Australian and New Zealand Intensive Care Research Centre

Among the 14 studies in Heart Arrest with a site in Australia, this one is one of 2 that started in 2019, is one of 5 observational ones, and was the 11th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

3 of the 14 studies in Heart Arrest with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Heart Arrest with a site in Australia, or all of them as a file.
02

Study summary

ECMO is associated with significant costs, risks and requires specialist training and expertise. EXCEL is a novel, high-quality, detailed prospective registry of patients requiring ECMO in Australia and New Zealand. The registry provides information on patient selection, complications, costs and patient reported outcome measures. EXCEL uses the Theoretical Domains Framework to identify evidence-practice gaps and explore barriers and enablers to tailor implementation of evidence

Read the detailed description

The aim of EXCEL is to generate a bi-national multidisciplinary network of integrated care for patients suffering acute cardiac or respiratory failure or cardiac arrest requiring extracorporeal membrane oxygenation (ECMO) to monitor long term outcomes and identify best practice.

Each year around 130,000 Australians and New Zealanders are admitted to an intensive care unit (ICU). The sickest patients in the ICU who have severe failure of the heart or lungs may require an external machine to oxygenate their blood in addition to a mechanical ventilator. This intervention, called extracorporeal membrane oxygenation (ECMO), involves circulating all of the patient's blood through large cannulae to external machinery every minute. It has the capability of completely replacing a non-functioning heart or lungs for days to weeks on end. These critically ill patients who require ECMO are the sickest in the hospital with only 42% hospital survival. The use of ECMO has doubled in Australia and New Zealand and globally over five years, and in the USA has increased by 433%.

The use of ECMO is associated with significant costs and risks, and it requires specialist training and expertise. In order to prepare for the organisation of these complex interventions in the ICU across regions, the investigators need to have accurate data on patients undergoing ECMO. The investigators monitor and review current practice in ECMO services by providing robust binational registry data to service providers and clinicians with a closed-loop feedback system. EXCEL explores barriers and enablers to evidence-based care in ECMO services and providing a platform to embed clinical trials. The investigators will translate findings with greater capacity, reach, and impact to drive measureable change in practice and improve patient-centred outcomes.

The EXCEL Partnership represents a novel, coordinated effort to create a high-quality, detailed, prospective registry of patients requiring ECMO at ECMO centres. A tailored, detailed ECMO registry (EXCEL) can be used to address specific safety concerns, clinical questions and process of care issues. As a result, EXCEL can be designed and implemented to answer new investigator-initiated, hypothesis-driven clinical questions.

03

Conditions studied

  • Critically Ill
  • Acute Respiratory Failure
  • Acute Heart Failure
  • Cardiac Arrest

Browse trials for

Keywords

  • Intensive Care
  • Critical Care
  • Extracorporeal Membrane Oxygenation
  • Extracorporeal Life Support
04

In context

Heart Arrest Reclassified

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 200 across 376 observational studies indexed under Heart Arrest.

Browse Heart Arrest studies →

Lead sponsor

Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Compared within Heart Arrest, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to hospitals with a primary diagnosis of acute heart failure, respiratory failure or cardiac arrest and received ECMO at participating ECMO centres.

Eligibility criteria

Inclusion Criteria:

  • Patients admitted to adult hospitals and receive ECMO in Australia and New Zealand

Nil Exclusion Criteria

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
07

What researchers measure

Primary outcomes

  1. Disability-free survival at 6 months, defined as alive and free of disability, measured with the World Health Organisation's Disability Assessment Schedule (WHODAS 2.0) score of <25%.

    WHODAS 2.0 measured using a trained, blinded assessor via telephone interview. The WHODAS scores are calculated using the sum of the six domain scores. These domain scores are then converted to a metric score ranging from 0 to 100 (where 0= no disability; 100= full disability)

    Time frame: At 6 months from study enrolment

Secondary outcomes

  1. Number of participants with adverse events including major bleeding up to 28 days after ECMO, infection, thrombosis (in the ECMO cannulae or in the patient) and limb ischaemia

    All adverse events are recorded determined by treating clinician

    Time frame: Up to 28 days after ECMO initiation

  2. Healthcare utilization - caseload per centre

    ECMO patient numbers (caseload per centre)

    Time frame: Up to 12 months from study enrolment

  3. Healthcare utilization - ECMO initiation timing

    Timing of ECMO initiation by staff including an ECMO retrieval team

    Time frame: Up to 12 months from study enrolment

  4. Healthcare utilization - number of staff members required to manage ECMO

    Staff numbers required for the provision of ECMO in ICU and the training required for these staff members to perform their role.

    Time frame: Up to 12 months from study enrolment

  5. Healthcare utilization - hospital length of stay

    Hospital and in-patient rehabilitation length of stay including hospital readmissions and time spent in ICU

    Time frame: Up to 12 months from study enrolment

  6. Healthcare costs

    Number of resources including staff and, equipment and blood products utilised whilst the patient was receiving hospital care until 6 months following hospital admission.

    Time frame: Measured from ECMO commencement to hospital discharge until 6 months following hopsital admission.

  7. Health-related quality of life at baseline, 6 and 12 months using the EQ5D-5L

    Measured using the EQ5D-5L, delivered by a trained, blinded assessor via telephone interview. The EQ5D includes an analogue scale that asks the patient to rate their health on a scale of 0 to 100. (Where 0= worst health imaginable; 100= best health imaginable)

    Time frame: At 6 and 12 months from study enrolment. Retrospective baseline measured at 6 months.

  8. Number of patients with disability at 6 and 12 months

    Measured using the WHODAS 2.0, delivered by a trained, blinded assessor via telephone interview

    Time frame: At 6 and 12 months from study enrolment

  9. Psychological function at 12 months

    Measured using the EQ5D-5L, delivered by a trained, blinded assessor via telephone interview

    Time frame: At 12 months from study enrolment

  10. Return to work at 6 months

    Return to work measured bu the WHODAS 2.0, delivered by a trained, blinded assessor via telephone interview

    Time frame: At 6 months from study enrolment

  11. Disability at baseline, 6 and 12 months

    Patient reported disability using a disability scale, delivered by a trained, blinded assessor via telephone interview

    Time frame: Measured at 6 and 12 months. Retrospective baseline disability measured at 6 months.

  12. Activities of daily living at 6 and 12 months

    Activities of daily living measured at 6 and 12 month using the ADL and IADL, delivered by a trained, blinded assessor via telephone interview

    Time frame: Measured at 6 and 12 months

  13. Cognitive function at 12 months

    Cognitive function measured at 12 months using the MOCA Blind, delivered by a trained, blinded assessor via telephone interview

    Time frame: Measured at 12 months

  14. Number patients who survive to 12 months following ECMO initiation

    Measured by Research Coordinators at each of the participating sites

    Time frame: At 12 months from study enrolment

08

Study locations

28 of 29 sites recruiting
09

References and documents

Publications

  • Hodgson CL, Higgins AM, Bailey MJ, Anderson S, Bernard S, Fulcher BJ, Koe D, Linke NJ, Board JV, Brodie D, Buhr H, Burrell AJC, Cooper DJ, Fan E, Fraser JF, Gattas DJ, Hopper IK, Huckson S, Litton E, McGuinness SP, Nair P, Orford N, Parke RL, Pellegrino VA, Pilcher DV, Sheldrake J, Reddi BAJ, Stub D, Trapani TV, Udy AA, Serpa Neto A; EXCEL Study Investigators on behalf of the International ECMO Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Incidence of death or disability at 6 months after extracorporeal membrane oxygenation in Australia: a prospective, multicentre, registry-embedded cohort study. Lancet Respir Med. 2022 Nov;10(11):1038-1048. doi: 10.1016/S2213-2600(22)00248-X. Epub 2022 Sep 26. PubMed 36174613 ↗
  • Fulcher BJ, Nicholson AJ, Linke NJ, Berkovic D, Hodgson CL; EXCEL Study Investigators and the International ECMO Network. The perceived barriers and facilitators to implementation of ECMO services in acute hospitals. Intensive Care Med. 2020 Nov;46(11):2115-2117. doi: 10.1007/s00134-020-06187-z. Epub 2020 Jul 23. No abstract available. PubMed 32705292 ↗
  • Linke NJ, Fulcher BJ, Engeler DM, Anderson S, Bailey MJ, Bernard S, Board JV, Brodie D, Buhr H, Burrell AJC, Cooper DJ, Fan E, Fraser JF, Gattas DJ, Higgins AM, Hopper IK, Huckson S, Litton E, McGuinness SP, Nair P, Orford N, Parke RL, Pellegrino VA, Pilcher DV, Sheldrake J, Reddi BAJ, Stub D, Trapani TV, Udy AA, Hodgson CL; EXCEL Investigators. A survey of extracorporeal membrane oxygenation practice in 23 Australian adult intensive care units. Crit Care Resusc. 2020 Jun;22(2):166-170. doi: 10.51893/2020.2.sur7. No abstract available. PubMed 32389109 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Dec 2026, 94 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 94 months is above that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2018
First posted
Jan 4, 2019
StartActual
Feb 1, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03793257
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Collaborators
National Health and Medical Research Council, Australia, Extracorporeal Life Support Organization, National Heart Foundation, Australia, The Alfred, Barwon Health, Fiona Stanley Hospital, The Prince Charles Hospital, Royal Prince Alfred Hospital, Sydney, Australia, St Vincent's Hospital, Sydney
Responsible party
Sponsor
First posted
Jan 4, 2019
Start date
Feb 1, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 15, 2023

Study contacts

Carol L Hodgson, PhD
Contact
carol.hodgson@monash.edu
+613 9903 0598
Ben Fulcher
Contact
bentley.fulcher@monash.edu
+613 9903 0930
Carol L Hodgson, PhD
study chair · Australian and New Zealand Intensive Care Research Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion